Sensus Healthcare Announces Preliminary 2023 Revenue Exceeds $23 Million

Ships more than 60 SRT units in 2023
To report full financial results and hold conference call on February 8^th

BOCA RATON, Fla. , Jan. 23, 2024 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announces preliminary unaudited financial results for the three and 12 months ended December 31, 2023.

The company expects to report revenue for the fourth quarter of 2023 of more than $12 million, with full-year revenue expected to exceed $23 million.  

“We are delighted to report a strong uptick in our business during the fourth quarter and to achieve our guidance to ship more than 60 SRT systems during 2023,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare. “Our customers were impacted by inflation and, to a lesser extent, interest rates during the first three quarters of 2023. Yet as anticipated, they adjusted to the economic environment as the year progressed.  Further, utilization of superficial radiotherapy to treat non-melanoma skin cancer continued to increase, driven by favorable reimbursement, an aging population and clinical results that are as good, if not better than, Mohs surgery.”

Mr. Sardano added, “We expect heightened interest from prospective customers at three important trade shows during the first quarter of 2024, namely the Winter Clinical and the South Beach Symposium in February and the American Academy of Dermatology annual meeting in March.  Sensus will have a strong presence at these conferences and will be demonstrating our SRT systems and other products and services.”

Sensus Healthcare plans to announce 2023 fourth quarter and full-year financial results and hold an investment community conference call after the close of the U.S. stock markets on February 8, 2024.  Conference call details including participation instructions will be provided at a later date.

About Sensus Healthcare

Sensus Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging its cutting-edge superficial radiotherapy (SRT) technology, the company provides healthcare providers with a highly effective, patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.